MindRank

Focus: MindRank is an AI-driven drug discovery biotech focused on metabolic diseases, headquartered in Shanghai and publicly listed. The company leverages artificial intelligence to accelerate preclinical and clinical drug development.

Metabolic Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Total Funding

$23M

Open Jobs

About MindRank

AI assessmentNot Hiring

No open roles listed right now. Follow MindRank to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

MDR-001

Obesity &Amp; Overweight

PHASE_1

Clinical Trials (3)

NCT07550621Drug-Drug Interaction Study of MDR-001 With Rifampin and Itraconazole in Healthy Adult Participants

Phase 1

Help build intelligence for MindRank

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage pipeline with multiple Phase 1-3 programs in obesity, a high-demand therapeutic area with significant commercial upside
AI-first drug discovery approach offers exposure to cutting-edge computational biology and emerging biotech methodologies
Public company status provides liquidity, stability, and potential equity upside tied to clinical milestones

Watch Out For

No active job openings currently listed, suggesting limited near-term hiring despite public status
Sparse public profile (no publications, limited news data, missing financial metrics) raises transparency and disclosure concerns
Early-stage pipeline (lead asset MDR-001 in Phase 1-3 only) means 5-10+ years before commercial revenue and significant execution risk

Generated by Claude from MindRank's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NCT07110766Phase Ib Clinical Study on the Efficacy and Safety of MDR-001 in Patients Who Are Obesity or Overweight

Phase 1

NCT07550634Pharmacokinetics and Safety of MDR-001 in Mild and Moderate Hepatic Impairment

Phase 1

MDR-001

Overweight and Obese Volunteers

PHASE_1_2

Clinical Trials (1)

NCT06778850A Phase I/IIa Clinical Study to Assess the Single and Multiple Ascending Doses of MDR-001 Tablets in Healthy Participants and Obese/ Overweight Participants

Phase 1/2

MDR-001

Obesity

PHASE_2

Clinical Trials (1)

NCT06606483A Study to Evaluate the Efficacy and Safety of MDR-001 in Subjects Who Are Obesity or Overweight

Phase 2

MDR-001

Overweight or Obesity

PHASE_3

Clinical Trials (1)

NCT07274137A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE）